Nothing Special   »   [go: up one dir, main page]

WO2007033020A3 - Ophthalmic formulation for treatment of dry eye - Google Patents

Ophthalmic formulation for treatment of dry eye Download PDF

Info

Publication number
WO2007033020A3
WO2007033020A3 PCT/US2006/035069 US2006035069W WO2007033020A3 WO 2007033020 A3 WO2007033020 A3 WO 2007033020A3 US 2006035069 W US2006035069 W US 2006035069W WO 2007033020 A3 WO2007033020 A3 WO 2007033020A3
Authority
WO
WIPO (PCT)
Prior art keywords
dry eye
treatment
synthetic
ophthalmic formulation
preservative
Prior art date
Application number
PCT/US2006/035069
Other languages
French (fr)
Other versions
WO2007033020A2 (en
Inventor
Robert J Meyering
Original Assignee
Bausch & Lomb
Robert J Meyering
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb, Robert J Meyering filed Critical Bausch & Lomb
Publication of WO2007033020A2 publication Critical patent/WO2007033020A2/en
Publication of WO2007033020A3 publication Critical patent/WO2007033020A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to formulations for topical use comprising US FDA monograph approved 'Dry eye' active ingredients in combination with electrolytes synthetic glycoproteins, synthetic proteins, synthetic enzymes and/or synthetic peptides in both a preservative and preservative free formulation/system for the treatment of dry eye and attendant inflammation.
PCT/US2006/035069 2005-09-13 2006-09-08 Ophthalmic formulation for treatment of dry eye WO2007033020A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71672405P 2005-09-13 2005-09-13
US60/716,724 2005-09-13

Publications (2)

Publication Number Publication Date
WO2007033020A2 WO2007033020A2 (en) 2007-03-22
WO2007033020A3 true WO2007033020A3 (en) 2007-07-19

Family

ID=37865463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/035069 WO2007033020A2 (en) 2005-09-13 2006-09-08 Ophthalmic formulation for treatment of dry eye

Country Status (1)

Country Link
WO (1) WO2007033020A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2947274C (en) * 2014-04-28 2019-03-19 Hampton Technologies Ophthalmic compositions and methods for treating eyes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652209A (en) * 1994-04-29 1997-07-29 University Of Miami Use of secretory products of human lacrimal gland acinar epithelia for tear replacement therapy
US6043213A (en) * 1996-04-19 2000-03-28 R-Tech Ueno, Ltd. Drug composition comprising albumin as active ingredient
US20040126419A1 (en) * 2001-01-30 2004-07-01 Isis Innovation Limited Artificial tear formulation
WO2005084635A2 (en) * 2004-03-02 2005-09-15 Institute Of Ophthalmology Pharmaceutical ocular preparations suitable for the treatment of the ocular surface and related disorders/diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652209A (en) * 1994-04-29 1997-07-29 University Of Miami Use of secretory products of human lacrimal gland acinar epithelia for tear replacement therapy
US6043213A (en) * 1996-04-19 2000-03-28 R-Tech Ueno, Ltd. Drug composition comprising albumin as active ingredient
US20040126419A1 (en) * 2001-01-30 2004-07-01 Isis Innovation Limited Artificial tear formulation
WO2005084635A2 (en) * 2004-03-02 2005-09-15 Institute Of Ophthalmology Pharmaceutical ocular preparations suitable for the treatment of the ocular surface and related disorders/diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OHASHI ET AL: "Laboratory findings in tear fluid analysis", CLINICA CHIMICA ACTA, AMSTERDAM, NL, vol. 369, no. 1, 15 July 2006 (2006-07-15), pages 17 - 28, XP005465744, ISSN: 0009-8981 *
ZHOU L ET AL: "Characterisation of human tear proteins using high-resolution mass spectrometry", ANNALS OF THE ACADEMY OF MEDICINE, SINGAPORE, ACADEMY OF MEDICINE, SG, vol. 35, no. 6, June 2006 (2006-06-01), pages 400 - 407, XP009074070, ISSN: 0304-4602 *

Also Published As

Publication number Publication date
WO2007033020A2 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
WO2006082588A3 (en) Method and device for ophthalmic administration of active pharmaceutical ingredients
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2003064449A3 (en) Bioactive keratin peptides
EP2422794A3 (en) Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
WO2006055454A3 (en) Ophthalmic compositions and methods for treating eyes
WO2002009637A3 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
WO2008111562A1 (en) Whitening agent
WO2002049615A3 (en) Artificial tear composition containing a combination of three demulcents
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
WO2007050369A3 (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
WO2007056105A3 (en) Human growth hormone patch formulations
WO2004009038A3 (en) Cosmetic preparations with antibacterial properties comprising glycyrrhetinic acid
WO2003018059A3 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
WO2001034641A3 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
AU2003296692A1 (en) Lipidic protein-transfer systems and cosmetic/dermatological use thereof
WO2008145849A3 (en) Pharmaceutical and/or cosmetic composition containing aconitase-activating active ingredients
WO2007134118A3 (en) Protein based composition and methods of using same
WO2022184854A3 (en) Formulations of ace2 fc fusion proteins
WO2007135268A3 (en) Use of peptides as active slimming ingredients
CA2420640A1 (en) Combination preparations of 3-n-formyl hydroxy amino propyl phosphonic acid derivatives or 3-n-acetyl hydroxy amino propyl phosphonic acid derivatives together with special pharmaceutical active ingredients
EP2371379A3 (en) New formulation for increasing bioavailability of neurturin
WO2007033020A3 (en) Ophthalmic formulation for treatment of dry eye
AU1169999A (en) Aqueous ophthalmic formulations comprising chitosan
WO2006103354A3 (en) Dermatological and/or cosmetic composition containing proteins of the sirt family
WO2006018454A3 (en) Cosmetic preparation comprising hyaluronic acid and saponins for treatment of skin aging phenomena

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06814350

Country of ref document: EP

Kind code of ref document: A2